Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R

European Journal of Pharmacology

Volumn 584, Issue 2-3, 2008, Pages 424-434

  Akizuki, Osamu ^a   Inayoshi, Atsushi ^a   Kitayama, Tetsuya ^a   Yao, Kozo ^a   Shirakura, Shiro ^a   Sasaki, Katsutoshi ^a   Kusaka, Hideaki ^a   Matsubara, Masahiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Aldosterone; Benidipine; T type Ca2+ channel

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; BENIDIPINE; CALCISEPTINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CILNIDIPINE; EFONIDIPINE; MIBEFRADIL; NIFEDIPINE; STEROID 11BETA MONOOXYGENASE; VALSARTAN;

ADRENAL CORTEX CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PATCH CLAMP; PRIORITY JOURNAL; UPREGULATION;

ADRENAL CORTEX; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CELL LINE; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHLORIDE; RNA, MESSENGER; STEROID 11-BETA-HYDROXYLASE; TETRAZOLES; VALINE;

EID: 41149181485     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.001     Document Type: Article

References (36)

1. Barrett P.Q., Ertel E.A., Smith M.M., Nee J.J., and Cohen C.J. Voltage-gated calcium currents have two opposing effects on the secretion of aldosterone. Am. J. Physiol. 268 (1995) C985-C992
2. Bird I.M., Hanley N.A., Word R.A., Mathis J.M., McCarthy J.L., Mason J.I., and Rainey W.E. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology 133 (1993) 1555-1561
3. Bird I.M., Mathis J.M., Mason J.I., and Rainey W.E. Ca(2+)-regulated expression of steroid hydroxylases in H295R human adrenocortical cells. Endocrinology 136 (1995) 5677-5684
4. Catterall W.A., Perez-Reyes E., Snutch T.P., and Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57 (2005) 411-425
5. Clyne C.D., White P.C., and Rainey W.E. Calcium regulates human CYP11B2 transcription. Endocr. Res. 22 (1996) 485-492
6. De Weille J.R., Schweitz H., Maes P., Tartar A., and Lazdunski M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2437-2440
7. Furukawa T., Nukada T., Miura R., Ooga K., Honda M., Watanabe S., Koganesawa S., and Isshiki T. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. 45 (2005) 241-246
8. Furukawa T., Yamakawa T., Midera T., Sagawa T., Mori Y., and Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 291 (1999) 464-473
9. Hansen P.B., Jensen B.L., Andreasen D., and Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ. Res. 89 (2001) 630-638
10. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers. Arch. 391 (1981) 85-100
11. Hayashi K., Ozawa Y., Fujiwara K., Wakino S., Kumagai H., and Saruta T. Role of actions of calcium antagonists on efferent arterioles-with special references to glomerular hypertension. Am. J. Nephrol. 23 (2003) 229-244
12. Hayashi K., Wakino S., Homma K., Sugano N., and Saruta T. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J. Pharmacol. Sci. 99 (2005) 221-227
13. Kawata T., Hashimoto S., and Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 30 (1997) 431-436
14. Kitakaze M., Karasawa A., Kobayashi H., Tanaka H., Kuzuya T., and Hori M. Benidipine: a new Ca2+ channel blocker with a cardioprotective effect. Cardiovasc. Drug Rev. 17 (1999) 1-15
15. Lai L., Chen J., Hao C.M., Lin S., and Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem. Biophys. Res. Commun. 348 (2006) 70-75
16. Lesouhaitier O., Chiappe A., and Rossier M.F. Aldosterone increases T-type calcium currents in human adrenocarcinoma (H295R) cells by inducing channel expression. Endocrinology 142 (2001) 4320-4330
17. Nakamura T., Obata J.E., Onitsuka M., Shimada Y., Yoshida Y., Kawachi H., and Shimizu F. Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis. Nephron 86 (2000) 315-326
18. Namba M., Kim S., Zhan Y., Nakao T., and Iwao H. Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension. Hypertens. Res. 25 (2002) 461-466
19. Masumoto K., Takeyasu A., Oizumi K., and Kobayashi T. Studies of 1,4-dihydropyridine Ca antagonist CS-905. (I) Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC). Yakugaku Zasshi 115 (1995) 213-220
20. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev. 83 (2003) 117-161
21. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
22. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999) 709-717
23. Rossier M.F., Burnay M.M., Vallotton M.B., and Capponi A.M. Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells. Endocrinology 137 (1996) 4817-4826
24. Rossier M.F., Ertel E.A., Vallotton M.B., and Capponi A.M. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J. Pharmacol. Exp. Ther. 287 (1998) 824-831
25. Rossier M.F., Python C.P., Capponi A.M., Schlegel W., Kwan C.Y., and Vallotton M.B. Blocking T-type calcium channels with tetrandrine inhibits steroidogenesis in bovine adrenal glomerulosa cells. Endocrinology 132 (1993) 1035-1043
26. Sato A., Saruta T., and Funder J.W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 29 (2006) 211-216
27. Spat A., and Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol. Rev. 84 (2004) 489-539
28. Struthers A.D., and MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc.Res. 61 (2004) 663-670
29. Teramoto N., Ogata R., Okabe K., Kameyama A., Kameyama M., Watanabe T.X., Kuriyama H., and Kitamura K. Effects of calciseptine on unitary barium channel currents in guinea-pig portal vein. Pflugers Arch. 432 (1996) 462-470
30. Tanaka H., and Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type Ca(2+) channels. Cardiovasc. Drug Rev. 20 (2002) 81-92
31. Yagci A., and Müller J. Induction of steroidogenic enzymes by potassium in cultured rat zona glomerulosa cells depends on calcium influx and intact protein synthesis. Endocrinology 137 (1996) 4331-4338
32. Yao K., Nagashima K., and Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J. Pharmacol. Sci. 100 (2006) 243-261
33. Yao K., Sato H., Ina Y., Suzuki K., Ohno T., and Shirakura S. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens. Res. 26 (2003) 635-641
34. Yao K., Sato H., Sonoda R., Ina Y., Suzuki K., and Ohno T. Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens. Res. 26 (2003) 76-569
35. Yuan J., Jia R., and Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J. Biochem. Mol. Biol. 40 (2007) 180-188
36. Yue W., Kimura S., Fujisawa Y., Tian R., Li F., Rahman M., Nishiyama A., Fukui T., and Abe Y. Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens. Res. 24 (2001) 429-436